CN1251097A - 具有血管生成抑制活性的酞嗪类化合物 - Google Patents
具有血管生成抑制活性的酞嗪类化合物 Download PDFInfo
- Publication number
- CN1251097A CN1251097A CN98803604A CN98803604A CN1251097A CN 1251097 A CN1251097 A CN 1251097A CN 98803604 A CN98803604 A CN 98803604A CN 98803604 A CN98803604 A CN 98803604A CN 1251097 A CN1251097 A CN 1251097A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- amino
- group
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH31597 | 1997-02-13 | ||
CH315/97 | 1997-02-13 | ||
PCT/EP1998/000764 WO1998035958A1 (en) | 1997-02-13 | 1998-02-11 | Phthalazines with angiogenesis inhibiting activity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1251097A true CN1251097A (zh) | 2000-04-19 |
CN1251097B CN1251097B (zh) | 2011-10-19 |
Family
ID=4184213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN988036045A Expired - Fee Related CN1251097B (zh) | 1997-02-13 | 1998-02-11 | 具有血管生成抑制活性的酞嗪类化合物 |
Country Status (32)
Country | Link |
---|---|
US (3) | US6258812B1 (zh) |
EP (1) | EP0970070B1 (zh) |
JP (1) | JP3544675B2 (zh) |
KR (1) | KR100441362B1 (zh) |
CN (1) | CN1251097B (zh) |
AR (1) | AR011135A1 (zh) |
AT (1) | ATE278686T1 (zh) |
AU (1) | AU731852B2 (zh) |
BR (1) | BR9807685B1 (zh) |
CA (1) | CA2281721C (zh) |
CO (1) | CO4950519A1 (zh) |
CY (1) | CY2550B1 (zh) |
CZ (1) | CZ297534B6 (zh) |
DE (1) | DE69826841T2 (zh) |
DK (1) | DK0970070T3 (zh) |
ES (1) | ES2234097T3 (zh) |
HU (1) | HU227972B1 (zh) |
ID (1) | ID23698A (zh) |
IL (1) | IL131273A0 (zh) |
MY (1) | MY128645A (zh) |
NO (1) | NO317367B1 (zh) |
NZ (1) | NZ337064A (zh) |
PE (1) | PE52499A1 (zh) |
PL (1) | PL197371B1 (zh) |
PT (1) | PT970070E (zh) |
RU (1) | RU2207132C2 (zh) |
SI (1) | SI0970070T1 (zh) |
SK (1) | SK285757B6 (zh) |
TR (1) | TR199901953T2 (zh) |
TW (1) | TWI250151B (zh) |
WO (1) | WO1998035958A1 (zh) |
ZA (1) | ZA981155B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1330308C (zh) * | 2001-09-12 | 2007-08-08 | 诺瓦提斯公司 | 含有4-吡啶基甲基酞嗪的联合产品及其应用 |
CN100372535C (zh) * | 2002-09-24 | 2008-03-05 | 诺瓦提斯公司 | 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途 |
CN101116664B (zh) * | 2007-08-28 | 2010-05-19 | 山东省科学院生物研究所 | 化合物1-(4-氯苯胺基)-4-(4-甲基吡啶基)-2,3-二氮杂萘的应用 |
WO2016123796A1 (en) * | 2015-02-06 | 2016-08-11 | Abbvie Inc. | Substituted phthalazines |
Families Citing this family (277)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
AU733551B2 (en) | 1996-09-25 | 2001-05-17 | Astrazeneca Ab | Qinoline derivatives inhibiting the effect of growth factors such as VEGF |
CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
JP4959049B2 (ja) | 1997-08-22 | 2012-06-20 | アストラゼネカ・ユーケイ・リミテッド | 血管新生阻害剤としてのオキシインドリルキナゾリン誘導体 |
ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
DK1105136T3 (da) * | 1998-08-13 | 2007-10-15 | Novartis Ag | Fremgangsmåde til behandling af okulære neovaskulære sygdomme |
WO2000059509A1 (en) * | 1999-03-30 | 2000-10-12 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
US6271233B1 (en) | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
US6689883B1 (en) | 1999-09-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
DOP2000000070A (es) * | 1999-09-28 | 2002-02-28 | Bayer Healthcare Llc | Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis |
SK287401B6 (sk) | 1999-11-05 | 2010-09-07 | Astrazeneca Ab | Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
DE19963607B4 (de) * | 1999-12-23 | 2005-12-15 | Schering Ag | Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen |
AU2001231710A1 (en) | 2000-02-09 | 2001-08-20 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
US7087608B2 (en) | 2000-03-03 | 2006-08-08 | Robert Charles Atkins | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
US7977333B2 (en) | 2000-04-20 | 2011-07-12 | Bayer Healthcare Llc | Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
EP1166798A1 (en) * | 2000-06-23 | 2002-01-02 | Schering Aktiengesellschaft | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use |
KR20030036238A (ko) * | 2000-06-23 | 2003-05-09 | 쉐링 악티엔게젤샤프트 | VEGF/VEGF 수용체 및 안지오포이에틴/Tie수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ) |
EP1166799A1 (en) * | 2000-06-28 | 2002-01-02 | Schering Aktiengesellschaft | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II) |
JP2004505965A (ja) * | 2000-08-09 | 2004-02-26 | アストラゼネカ アクチボラグ | 化合物 |
US6903101B1 (en) * | 2000-08-10 | 2005-06-07 | Bayer Pharmaceuticals Corporation | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
KR100589032B1 (ko) | 2000-10-20 | 2006-06-14 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
CN100400518C (zh) * | 2000-10-30 | 2008-07-09 | 库多斯药物有限公司 | 2,3-二氮杂萘酮衍生物 |
CA2427184A1 (en) * | 2000-11-22 | 2002-05-30 | Novartis Ag | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
US7096566B2 (en) | 2001-01-09 | 2006-08-29 | Black & Decker Inc. | Method for making an encapsulated coil structure |
US7814641B2 (en) * | 2001-01-09 | 2010-10-19 | Black & Decker Inc. | Method of forming a power tool |
CN104274442A (zh) | 2001-02-19 | 2015-01-14 | 诺华股份有限公司 | 癌症的治疗 |
GB0111078D0 (en) * | 2001-05-04 | 2001-06-27 | Novartis Ag | Organic compounds |
DK1392313T3 (da) | 2001-05-16 | 2007-06-25 | Novartis Ag | Kombination omfattende N-{5-[4-(4-methyl-piperazino-methyl)-benzoyl-amido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidin-amin og et biphosphonat |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
US20030073692A1 (en) | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
SI1427420T1 (sl) * | 2001-09-12 | 2006-12-31 | Novartis Ag | Uporaba kombinacije, ki vsebuje 4-piridilmetilftalazine za zdravljenje raka |
JP4130179B2 (ja) * | 2001-09-27 | 2008-08-06 | ノバルティス アクチエンゲゼルシャフト | 骨髄腫を処置するためのc−kit阻害剤の使用 |
NZ532418A (en) * | 2001-10-25 | 2007-02-23 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor and a microtubule interfering agent |
WO2003059354A2 (en) * | 2001-12-21 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
RU2316554C2 (ru) * | 2001-12-27 | 2008-02-10 | Тереванс, Инк. | Производные индолина, используемые как ингибиторы протеинкиназы |
US20030171375A1 (en) * | 2002-02-13 | 2003-09-11 | Brazzell Romulus Kimbro | Method for treating ocular neovascular diseases |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
AU2003233198A1 (en) * | 2002-04-30 | 2003-11-17 | Novartis Ag | Method for decreasing capillary permeability in the retina |
EP1944026B1 (en) | 2002-05-16 | 2013-06-26 | Novartis AG | Use of EDG receptor binding agents in cancer |
CN100355423C (zh) * | 2002-06-28 | 2007-12-19 | 诺瓦提斯公司 | 用于治疗肿瘤的包含血管抑制化合物和烷化剂的组合 |
EP1576129A4 (en) * | 2002-08-09 | 2008-01-23 | Theravance Inc | ONCOKINASE FUSION POLYPEPTIDES ASSOCIATED WITH HYPERPROLIFERATIVE DISORDERS, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES AND METHODS OF DETECTION AND IDENTIFICATION THEREOF |
GB0223341D0 (en) * | 2002-10-08 | 2002-11-13 | Groningen Acad Ziekenhuis | Organic compounds |
US20060148810A1 (en) * | 2002-10-10 | 2006-07-06 | Frank Giles | Treatment of amm |
US7268137B2 (en) * | 2002-11-07 | 2007-09-11 | Campochiaro Peter A | Ocular therapy |
AU2003288034A1 (en) * | 2002-11-12 | 2004-06-03 | Novartis Ag | Treatment of mesothelioma |
US7094785B1 (en) | 2002-12-18 | 2006-08-22 | Cornell Research Foundation, Inc. | Method of treating polycythemia vera |
EP1581228A1 (en) * | 2002-12-20 | 2005-10-05 | Dana-Farber Cancer Institute, Inc. | Treatment of von hippel lindau disease |
AU2003292888A1 (en) * | 2002-12-27 | 2004-07-22 | Schering Aktiengesellschaft | Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
TWI369353B (en) | 2003-03-07 | 2012-08-01 | Santen Pharmaceutical Co Ltd | Novel compound having 4-pyridylalkylthio group as substituent |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
US20040242886A1 (en) * | 2003-04-30 | 2004-12-02 | Sandeep Gupta | Monocyclic diazodioxide based Bcl-2 protein antagonists related applications |
PE20050158A1 (es) | 2003-05-19 | 2005-05-12 | Irm Llc | Compuestos inmunosupresores y composiciones |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
KR20110129988A (ko) | 2003-07-18 | 2011-12-02 | 암젠 인코포레이티드 | 간세포 성장인자에 결합하는 특이 결합제 |
WO2005044788A1 (ja) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
DK1686997T3 (da) | 2003-11-18 | 2009-07-27 | Novartis Ag | Inhibitorer af mutantformen af KIT |
JP2007513967A (ja) * | 2003-12-11 | 2007-05-31 | セラヴァンス, インコーポレーテッド | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 |
DK1717229T3 (da) | 2004-02-17 | 2011-09-19 | Santen Pharmaceutical Co Ltd | Ny cyklisk forbindelse med 4-pyridylalkylthiogruppe med deri indført (u)substitueret amino |
EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
FR2868780B1 (fr) * | 2004-04-13 | 2008-10-17 | Sanofi Synthelabo | Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique |
EP1765313A2 (en) | 2004-06-24 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
EP2364699A1 (en) | 2004-09-13 | 2011-09-14 | Eisai R&D Management Co., Ltd. | Joint use of sulfonamide based compound with angiogenesis inhibitor |
US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
PE20060664A1 (es) * | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
ES2322175T3 (es) | 2004-09-17 | 2009-06-17 | EISAI R&D MANAGEMENT CO., LTD. | Composicion medicinal con estabilidad mejorada y gelificacion reducida. |
EP1827434B1 (en) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
WO2006093253A1 (ja) * | 2005-03-03 | 2006-09-08 | Santen Pharmaceutical Co., Ltd. | キノリルアルキルチオ基を有する新規環式化合物 |
US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
WO2006106914A1 (ja) | 2005-03-31 | 2006-10-12 | Santen Pharmaceutical Co., Ltd. | ピリミジニルアルキルチオ基を有する新規環式化合物 |
WO2006113172A1 (en) * | 2005-04-13 | 2006-10-26 | Novartis Ag | Use of vascular endothelial growth factor receptor inhibitors for the treatment of gastrointestinal, genitourinary, lymphoid and pulmonary cancers |
BRPI0609296A2 (pt) | 2005-05-02 | 2010-03-23 | Novartis Ag | uso de derivados de pirimidilaminobenzamida para o tratamento de mastocitose sistÊmica |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
EP1731153A1 (en) * | 2005-06-07 | 2006-12-13 | Schering Aktiengesellschaft | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)¬4-(4-pyridylmethyl)phthalazin-1-yl| and salts thereof |
EP1731154A1 (en) * | 2005-06-07 | 2006-12-13 | Schering Aktiengesellschaft | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)|4-(4-pyridylmethyl)pht halazin-1-yl| and salts thereof |
EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
GB0517205D0 (en) * | 2005-08-22 | 2005-09-28 | Novartis Ag | Organic compounds |
US7915410B2 (en) | 2005-09-09 | 2011-03-29 | Bristol-Myers Squibb Company | Acyclic IKur inhibitors |
CA2623034A1 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
PL2275103T3 (pl) | 2005-11-21 | 2014-09-30 | Novartis Ag | Inhibitory mTOR w leczeniu nowotworów neuroendokrynnych |
US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
EP1987023B1 (en) * | 2006-02-10 | 2010-11-24 | Amgen, Inc | Hydrate forms of amg706 |
PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
US20090098137A1 (en) | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
AR060358A1 (es) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
US8777120B2 (en) * | 2006-04-15 | 2014-07-15 | International Business Machines Corporation | Hydronic radiant flooring heating system |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP2021338A1 (en) | 2006-05-09 | 2009-02-11 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
CN101443002B (zh) | 2006-05-09 | 2012-03-21 | 诺瓦提斯公司 | 包含铁螯合剂和抗肿瘤药的组合及其用途 |
CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
GB0610925D0 (en) * | 2006-06-02 | 2006-07-12 | Novartis Ag | Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
BRPI0714665A2 (pt) | 2006-08-04 | 2012-03-13 | Takeda Pharmaceutical Company Limited | Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer |
CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
US20090286779A1 (en) | 2006-09-29 | 2009-11-19 | Novartis Ag | Pyrazolopyrimidines as lipid kinase inhibitors |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
ES2449482T3 (es) | 2007-01-09 | 2014-03-19 | Amgen Inc. | Derivados de bis-aril-amida útiles para el tratamiento de cáncer |
CA2676163A1 (en) | 2007-01-29 | 2008-08-07 | Santen Pharmaceutical Co., Ltd. | Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity |
US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
BRPI0807812A2 (pt) | 2007-02-15 | 2020-06-23 | Novartis Ag | Combinações de lbh589 com outros agentes terapêuticos para tratar câncer |
AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
EP2162445B1 (en) | 2007-06-05 | 2013-11-27 | Takeda Pharmaceutical Company Limited | Heterobicyclic compounds as kinase inhibitors |
US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
DK2188313T3 (en) | 2007-08-21 | 2017-12-11 | Amgen Inc | HUMAN C-FMS ANTI-BINDING PROTEINS |
WO2009025358A1 (ja) | 2007-08-23 | 2009-02-26 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
AU2008325608B2 (en) | 2007-11-09 | 2013-03-14 | Eisai R & D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
BRPI0820722A2 (pt) | 2007-12-20 | 2015-06-16 | Novartis Ag | Derivados de tiazol usados como inibidores de pi 3 cinases |
EP2628726A1 (en) | 2008-03-26 | 2013-08-21 | Novartis AG | Hydroxamate-based inhibitors of deacetylases b |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
JP5579619B2 (ja) | 2008-12-01 | 2014-08-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
DK2379497T3 (da) | 2008-12-18 | 2013-11-25 | Novartis Ag | Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre |
CA2747558A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | New salts |
AU2009327405A1 (en) | 2008-12-18 | 2011-06-30 | Novartis Ag | New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic |
WO2010072776A1 (en) | 2008-12-23 | 2010-07-01 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
UY32048A (es) | 2009-01-08 | 2010-03-26 | Boehringer Ingelheim Int | Derivados sustituido de 1-(sustituido)-3-metil-7-(sustituido)-8-(3-(R)-amino-piperidin-1-il)cantina y derivados sustituidos de 1-(sustituido) - 4 - fluoropirrolidin- 2 - carbonitrilo y sus sales famacéuticamente aceptables como inhibidores de DPP-4 y aplicaciones. |
JP2012516345A (ja) | 2009-01-29 | 2012-07-19 | ノバルティス アーゲー | 星細胞腫治療用置換ベンゾイミダゾール |
TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
NZ619520A (en) | 2009-02-13 | 2015-06-26 | Boehringer Ingelheim Int | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
US8530492B2 (en) | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
ES2475945T3 (es) | 2009-06-26 | 2014-07-11 | Novartis Ag | Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17 |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
MX2012001838A (es) | 2009-08-12 | 2012-02-29 | Novartis Ag | Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion. |
CN105078978A (zh) | 2009-08-17 | 2015-11-25 | 因特利凯公司 | 杂环化合物及其用途 |
EP2467383A1 (en) | 2009-08-20 | 2012-06-27 | Novartis AG | Heterocyclic oxime compounds |
EA201200321A1 (ru) | 2009-08-26 | 2012-09-28 | Новартис Аг | Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4 |
CN102596963A (zh) | 2009-09-10 | 2012-07-18 | 诺瓦提斯公司 | 二环杂芳基的醚衍生物 |
WO2011039367A2 (en) | 2009-10-02 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Therapeutic uses of pharmaceutical compositions |
AU2010317167B2 (en) | 2009-11-04 | 2012-11-29 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as MEK inhibitors |
JP2013512215A (ja) | 2009-11-25 | 2013-04-11 | ノバルティス アーゲー | 二環式ヘテロアリールのベンゼン縮合6員酸素含有ヘテロ環誘導体 |
CN102753161A (zh) | 2009-11-27 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗 |
GEP20135998B (en) | 2009-12-08 | 2013-12-25 | Novartis Ag | Heterocyclic sulfonamide derivatives |
AU2012265844A1 (en) | 2009-12-08 | 2013-05-02 | Novartis Ag | Heterocyclic sulfonamide derivatives |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
ES2935300T3 (es) | 2010-05-05 | 2023-03-03 | Boehringer Ingelheim Int | Combiterapia |
CN102947275A (zh) | 2010-06-17 | 2013-02-27 | 诺瓦提斯公司 | 哌啶基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物 |
WO2011157787A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
CN106975074A (zh) | 2010-06-24 | 2017-07-25 | 勃林格殷格翰国际有限公司 | 糖尿病治疗 |
ES2573515T3 (es) | 2010-06-25 | 2016-06-08 | Eisai R&D Management Co., Ltd. | Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados |
SG186983A1 (en) | 2010-07-09 | 2013-02-28 | Genentech Inc | Anti-neuropilin antibodies and methods of use |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
US8946260B2 (en) | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
EP2640384A1 (en) | 2010-11-18 | 2013-09-25 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
AU2011329681A1 (en) | 2010-11-18 | 2013-05-30 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment based on hypoxic status |
CA2825605C (en) | 2011-01-31 | 2019-05-07 | Novartis Ag | Heterocyclic derivatives |
US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
CN103492390A (zh) | 2011-03-08 | 2014-01-01 | 诺瓦提斯公司 | 氟苯基双环杂芳基化合物 |
US8623885B2 (en) | 2011-03-23 | 2014-01-07 | Amgen Inc. | Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
ES2656218T3 (es) | 2011-04-28 | 2018-02-26 | Novartis Ag | Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
PT2722322T (pt) | 2011-06-16 | 2019-09-27 | Katholieke Univ Leuven K U Leuven R&D | Derivado de 1,3-di-oxo-indeno, seu sal farmaceuticamente aceitável ou isómero ótico, seu método de preparação, e composição farmacêutica contendo o mesmo como ingrediente ativo, antiviral |
EP2721007B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Cyclohexyl isoquinolinone compounds |
US8859535B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
WO2013010964A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
PL2771342T3 (pl) | 2011-10-28 | 2016-11-30 | Nowe pochodne puryny i ich zastosowanie w leczeniu chorób | |
JP5992054B2 (ja) | 2011-11-29 | 2016-09-14 | ノバルティス アーゲー | ピラゾロピロリジン化合物 |
US20140350014A1 (en) | 2011-12-23 | 2014-11-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
CA2859862A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
EP2794592A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096055A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
CN104125954A (zh) | 2011-12-23 | 2014-10-29 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
US10213432B2 (en) | 2012-05-16 | 2019-02-26 | Novartis Ag | Dosage regimen for a PI-3 kinase inhibitor |
JP6374862B2 (ja) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性糖尿病、特に、ladaの治療に使用するためのdpp−4阻害剤としてのキサンチン誘導体 |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP2872161B1 (en) | 2012-06-26 | 2020-12-16 | Del Mar Pharmaceuticals | Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations |
EP2890696A1 (en) | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
KR101630243B1 (ko) | 2012-12-14 | 2016-06-15 | 한국화학연구원 | 신규한 화합물, 이의 약학적으로 허용가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 |
JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
EP2948453B1 (en) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
WO2014124860A1 (en) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Specific pde4b-inhibitors for the treatment of diabetes mellitus |
JP2016512835A (ja) | 2013-03-15 | 2016-05-09 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせ及びそれらの使用 |
CA2903577C (en) | 2013-03-15 | 2023-10-17 | Boehringer Ingelheim International Gmbh | Use of linagliptin in cardio- and renoprotective antidiabetic therapy |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
EP2997377B1 (en) | 2013-05-14 | 2018-07-18 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
AU2014358773A1 (en) | 2013-12-06 | 2016-06-02 | Novartis Ag | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
MX2017001461A (es) | 2014-07-31 | 2017-05-11 | Novartis Ag | Terapia de combinacion. |
MX2017001980A (es) | 2014-08-28 | 2017-05-04 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y metodo para su produccion. |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
JP7041515B2 (ja) | 2015-01-08 | 2022-03-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 骨、骨髄、及び軟骨の誘導を提供する因子及び細胞 |
SG11201706630UA (en) | 2015-02-25 | 2017-09-28 | Eisai R&D Man Co Ltd | Method for suppressing bitterness of quinoline derivative |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
JO3746B1 (ar) | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
MX2017015896A (es) | 2015-06-16 | 2018-08-09 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
CA3002954A1 (en) | 2015-11-02 | 2017-05-11 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
MX2019007643A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibirores de kras g12c para tratar el cancer de pulmon, pancreatico o colorrectal. |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
CA3075046A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
CA3079076A1 (en) | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
EP3730483B1 (en) | 2017-12-21 | 2023-08-30 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | Class of pyrimidine derivative kinase inhibitors |
MX2020011582A (es) | 2018-05-04 | 2020-11-24 | Amgen Inc | Inhibidores de kras g12c y metodos para su uso. |
EP3788038B1 (en) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
MA52564A (fr) | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
ES2938987T3 (es) | 2018-06-01 | 2023-04-18 | Amgen Inc | Inhibidores de KRAS G12c y métodos de uso de los mismos |
MA52780A (fr) | 2018-06-11 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
WO2020050890A2 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
CA3103992A1 (en) | 2018-07-17 | 2020-01-23 | Boehringer Ingelheim International Gmbh | Cardiosafe antidiabetic therapy |
MX2021000554A (es) | 2018-07-17 | 2021-03-29 | Boehringer Ingelheim Int | Tratamiento antidiabetico cardiovascular y renal seguro. |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
AU2019384118A1 (en) | 2018-11-19 | 2021-05-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
EP3897855B1 (en) | 2018-12-20 | 2023-06-07 | Amgen Inc. | Kif18a inhibitors |
CA3123044A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
AU2019403486A1 (en) | 2018-12-20 | 2021-06-24 | Amgen Inc. | KIF18A inhibitors |
WO2020132649A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
KR20210146288A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로사이클릴 화합물 및 이의 용도 |
KR20210146287A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
JP2022532379A (ja) | 2019-05-14 | 2022-07-14 | ザ スクリプス リサーチ インスティテュート | 神経変性および代謝障害の処置のための化合物 |
WO2020236947A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
CA3147451A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
MX2022001302A (es) | 2019-08-02 | 2022-03-02 | Amgen Inc | Inhibidores de kif18a. |
WO2021026099A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
JP2022552873A (ja) | 2019-10-24 | 2022-12-20 | アムジエン・インコーポレーテツド | がんの治療におけるkras g12c及びkras g12d阻害剤として有用なピリドピリミジン誘導体 |
JP2022553857A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
US11608346B2 (en) | 2019-11-04 | 2023-03-21 | Revolution Medicines, Inc. | Ras inhibitors |
MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
TW202132296A (zh) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Kras g12c抑制劑化合物之改善的合成 |
MX2022005726A (es) | 2019-11-14 | 2022-06-09 | Amgen Inc | Sintesis mejorada del compuesto inhibidor de g12c de kras. |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
TW202140011A (zh) | 2020-01-07 | 2021-11-01 | 美商銳新醫藥公司 | Shp2抑制劑給藥和治療癌症的方法 |
MX2022016355A (es) | 2020-06-18 | 2023-04-03 | Revolution Medicines Inc | Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras. |
IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
TW202227460A (zh) | 2020-09-15 | 2022-07-16 | 美商銳新醫藥公司 | Ras抑制劑 |
AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
JP2024505256A (ja) * | 2021-01-28 | 2024-02-05 | ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド | 神経変性、変性及び代謝性障害の処置のための化合物並びにその使用 |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
WO2022271679A1 (en) * | 2021-06-21 | 2022-12-29 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
WO2023121413A1 (ko) * | 2021-12-24 | 2023-06-29 | 제일약품주식회사 | 신규한 바이사이클릭 헤테로사이클릴 화합물 및 이의 용도 |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE567431A (zh) * | 1957-05-07 | |||
US2960504A (en) | 1957-05-07 | 1960-11-15 | Ciba Pharm Prod Inc | 1-hydrazino, 4-pyridyl methyl-phthalazines |
GB1094044A (en) | 1965-07-12 | 1967-12-06 | Vantorex Ltd | Phthalazine derivatives |
DE1695994A1 (de) | 1967-05-05 | 1971-05-19 | Vantorex Ltd | Verfahren zur Herstellung von Phthalazinen |
GB1293565A (en) * | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
JPH03106875A (ja) * | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | 1―(3―ピリジルメチル)フタラジン誘導体 |
EP0600831A1 (de) * | 1992-11-27 | 1994-06-08 | Ciba-Geigy Ag | Phthalazinonderivate |
KR100189865B1 (ko) * | 1994-08-09 | 1999-06-01 | 나이또 하루오 | 축합 피리다진계 화합물 |
ES2162235T3 (es) | 1996-01-15 | 2001-12-16 | Janssen Pharmaceutica Nv | Piridazinaminas inhibidoras de la angiogenesis. |
DE19617863A1 (de) | 1996-04-23 | 1997-10-30 | Schering Ag | Phthalazinderivate, deren Herstellung und Verwendung als Arzneimittel |
CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
ITMI981670A1 (it) * | 1998-07-21 | 2000-01-21 | Zambon Spa | Derivati ftalazinici inibitori della fosfodiesterasi 4 |
DK1105136T3 (da) * | 1998-08-13 | 2007-10-15 | Novartis Ag | Fremgangsmåde til behandling af okulære neovaskulære sygdomme |
-
1998
- 1998-02-05 CO CO98005806A patent/CO4950519A1/es unknown
- 1998-02-11 AR ARP980100616A patent/AR011135A1/es active IP Right Grant
- 1998-02-11 SI SI9830726T patent/SI0970070T1/xx unknown
- 1998-02-11 PL PL335113A patent/PL197371B1/pl unknown
- 1998-02-11 CZ CZ0285399A patent/CZ297534B6/cs not_active IP Right Cessation
- 1998-02-11 KR KR10-1999-7007317A patent/KR100441362B1/ko not_active IP Right Cessation
- 1998-02-11 ID IDW990869D patent/ID23698A/id unknown
- 1998-02-11 DE DE69826841T patent/DE69826841T2/de not_active Expired - Lifetime
- 1998-02-11 CA CA002281721A patent/CA2281721C/en not_active Expired - Fee Related
- 1998-02-11 PE PE1998000098A patent/PE52499A1/es not_active Application Discontinuation
- 1998-02-11 NZ NZ337064A patent/NZ337064A/en not_active IP Right Cessation
- 1998-02-11 JP JP53533698A patent/JP3544675B2/ja not_active Expired - Fee Related
- 1998-02-11 TR TR1999/01953T patent/TR199901953T2/xx unknown
- 1998-02-11 BR BRPI9807685-0A patent/BR9807685B1/pt not_active IP Right Cessation
- 1998-02-11 HU HU0001046A patent/HU227972B1/hu not_active IP Right Cessation
- 1998-02-11 RU RU99119224/14A patent/RU2207132C2/ru active
- 1998-02-11 US US09/367,273 patent/US6258812B1/en not_active Expired - Lifetime
- 1998-02-11 MY MYPI98000541A patent/MY128645A/en unknown
- 1998-02-11 AT AT98908086T patent/ATE278686T1/de active
- 1998-02-11 ES ES98908086T patent/ES2234097T3/es not_active Expired - Lifetime
- 1998-02-11 EP EP98908086A patent/EP0970070B1/en not_active Expired - Lifetime
- 1998-02-11 AU AU66218/98A patent/AU731852B2/en not_active Ceased
- 1998-02-11 DK DK98908086T patent/DK0970070T3/da active
- 1998-02-11 PT PT98908086T patent/PT970070E/pt unknown
- 1998-02-11 WO PCT/EP1998/000764 patent/WO1998035958A1/en active IP Right Grant
- 1998-02-11 SK SK1096-99A patent/SK285757B6/sk not_active IP Right Cessation
- 1998-02-11 CN CN988036045A patent/CN1251097B/zh not_active Expired - Fee Related
- 1998-02-11 IL IL13127398A patent/IL131273A0/xx not_active IP Right Cessation
- 1998-02-12 ZA ZA981155A patent/ZA981155B/xx unknown
- 1998-03-17 TW TW087102062A patent/TWI250151B/zh not_active IP Right Cessation
-
1999
- 1999-08-12 NO NO19993888A patent/NO317367B1/no not_active IP Right Cessation
-
2001
- 2001-05-17 US US09/859,858 patent/US6514974B2/en not_active Expired - Fee Related
-
2003
- 2003-01-07 US US10/338,062 patent/US6710047B2/en not_active Expired - Fee Related
-
2006
- 2006-02-13 CY CY0600004A patent/CY2550B1/xx unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1330308C (zh) * | 2001-09-12 | 2007-08-08 | 诺瓦提斯公司 | 含有4-吡啶基甲基酞嗪的联合产品及其应用 |
CN100372535C (zh) * | 2002-09-24 | 2008-03-05 | 诺瓦提斯公司 | 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途 |
CN101116664B (zh) * | 2007-08-28 | 2010-05-19 | 山东省科学院生物研究所 | 化合物1-(4-氯苯胺基)-4-(4-甲基吡啶基)-2,3-二氮杂萘的应用 |
WO2016123796A1 (en) * | 2015-02-06 | 2016-08-11 | Abbvie Inc. | Substituted phthalazines |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1251097A (zh) | 具有血管生成抑制活性的酞嗪类化合物 | |
CN1152031C (zh) | 具有血管生成抑制活性的异喹啉衍生物 | |
CN1216867C (zh) | 2-氨基-烟酰胺衍生物及其作为vegf-受体酪氨酸激酶抑制剂的用途 | |
CN1324022C (zh) | 酪氨酸激酶抑制剂 | |
CN1083452C (zh) | 抑制蛋白质酪氨酸激酶介导的细胞增殖的吡啶并[2,3-d]嘧啶 | |
CN1221262C (zh) | 治疗炎性疾病的酞嗪衍生物 | |
CN1161352C (zh) | 喹唑啉衍生物 | |
CN1165536C (zh) | 与六元杂环稠合的取代的吡唑衍生物 | |
CN100345830C (zh) | 稠合杂芳基衍生物 | |
CN1252065C (zh) | 噌啉化合物 | |
CN1684951A (zh) | 新的嘧啶胺衍生物及其用途 | |
CN1674898A (zh) | 作为促旋酶和 /或拓扑异构酶 i v的抑制剂用于治疗细菌感染的 2 -脲基-6-杂芳基-3 h-苯并咪唑-4-羧酸衍生物和相关化合物 | |
CN1437594A (zh) | 用于治疗异常细胞生长的取代的双环衍生物 | |
CN1625555A (zh) | 喹唑啉化合物 | |
CN1378547A (zh) | 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4,3-d]嘧啶-7-酮类化合物 | |
CN1155572C (zh) | 吲哚类衍生物及其抗肿瘤用途 | |
CN1446212A (zh) | 具有vegf抑制活性的喹啉衍生物 | |
CN1115982A (zh) | 具有药理学活性的吡啶类衍生物及其制备方法 | |
CN1209127A (zh) | 三环酰胺类用于抑制g-蛋白功能及治疗增生疾病 | |
CN1511151A (zh) | 3-喹啉-2(1h)-亚基二氢吲哚-2-酮衍生物 | |
CN1509291A (zh) | 噁唑并嘧啶和呋喃并嘧啶化合物以及它们作为抗肿瘤药物的用途 | |
CN1694708A (zh) | TGFβ的抑制剂 | |
CN1032648C (zh) | 一种血小板活化因子拮抗剂的制备方法 | |
CN1198158A (zh) | 作为酪氨酸激酶抑制剂的双环4-芳烷基氨基嘧啶衍生物 | |
CN1347416A (zh) | 取代的3-氰基-[1.7],[1.5]和[1.8]-二氮杂萘酪氨酸激酶抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1025956 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Basel Patentee after: Novartis Ag Address before: Basel Patentee before: Novartis AG |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111019 Termination date: 20150211 |
|
EXPY | Termination of patent right or utility model |